Why the study?
Does intravenous dopamine increase hepatosplanchnic blood flow in patients without cardiac failure?
Does intravenous dopamine increase hepatosplanchnic blood flow in patients without cardiac failure?
Intravenous dopamine at 4-8 mcg/kg/min increases hepatosplanchnic blood flow in patients without heart failure, indicating that dopamine-induced increases in renal blood flow do not occur at the expense of hepatosplanchnic perfusion.
May increase hepatosplanchnic flow in non-failing hearts; hypothesis-generating and should not yet change practice.
Hepatosplanchnic blood flow (EHBF) was estimated with the single-injection method using indocyanine green in 10 patients without cardiac failure before and after 20 min of an intravenous infusion of dopamine. Five patients received 4 microgram/kg/min and another 5 patients 8 microgram/kg/min. The cardiac index (CI) was determined according to the Fick principle, and the arterio-hepatovenous oxygen difference (AV DO2 AO/HV) was measured. The mean increase in EHBF in the 10 patients was from 640 +/- 46 ml/min/m2 to 831 +/- 56 ml/min/m2 (p less than 0.001). The percentage of EHBF to CI increased from 24.1 +/- 2.0% to 26.4 +/- 1.6% (p less than 0.05). The mean AV DO2 AO/HV dropped from 49.6 +/- 3.8 ml/liter to 40.4+/- 2.9 ml/liter (p less than 0.005). We conclude that dopamine given at rates of 4 and 8 microgram/kg/min to patients whose hearts are well compensated increases hepatosplanchnic flow. Thus, the large increase in renal blood flow which occurs with dopamine is not at the expense of hepatosplanchnic blood flow.
No takes yet. Share an insight, caveat, or question.
Angehrn et al. (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: